Karbwang J, Thanavibul A, Molunto P, Na Bangchang K
Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Br J Clin Pharmacol. 1993 Apr;35(4):444-6. doi: 10.1111/j.1365-2125.1993.tb04165.x.
The pharmacokinetics of quinine were studied in six patients with hepatitis B infection (during acute and convalescent periods) and six healthy subjects. A single 10 mg kg-1 dose of quinine was given intravenously over 2 h. Pharmacokinetic parameters of quinine during the acute phase of the infection were not different from those during the recovery phase. However, when compared with those obtained from healthy subjects, significant changes were found. The terminal elimination half-life was prolonged (17 and 15 vs 10 h) and clearance was lower (2.9 and 2.3 vs 3.5 ml min-1 kg-1). Unbound quinine concentration in plasma at 2 h was approximately 10% of the total concentration in all subjects in the three study groups. A prolonged QTc interval (< 25%) was observed in all groups. The present data suggest that current dosage regimens of quinine used in the treatment of falciparum malaria may not be suitable for malaria patients with acute hepatitis or those who have had hepatitis within the past 3 months.
对6例乙型肝炎感染患者（急性期和恢复期）及6名健康受试者的奎宁药代动力学进行了研究。静脉内2小时给予单次10mg/kg剂量的奎宁。感染急性期奎宁的药代动力学参数与恢复期无差异。然而，与健康受试者相比，发现有显著变化。终末消除半衰期延长（17和15小时对10小时），清除率降低（2.9和2.3对3.5ml/min/kg）。三个研究组所有受试者在2小时时血浆中游离奎宁浓度约为总浓度的10%。所有组均观察到QTc间期延长（<25%）。目前的数据表明，用于治疗恶性疟原虫疟疾的奎宁现行给药方案可能不适用于急性肝炎的疟疾患者或过去3个月内患过肝炎的患者。
